• Announcement of Joint Research Collaboration with the University of Tokyo and Nara Medical University.
We are pleased to announce that our company has entered into a joint research agreement with the University of Tokyo Graduate School and Nara Medical University for the development of a therapeutic drug for rare blood diseases using bispecific DNA aptamers. (May 15, 2025)

• Strategic Partnership Agreement Signed with Kanematsu Chemicals Corporation.We are pleased to announce that we have entered into a basic strategic partnership agreement with Kanematsu Chemicals Corporation, a specialized trading company in the chemical and life sciences fields. (March 31, 2025)

• Joint Research Agreement with Professor Hoshino’s Laboratory at Kyushu University. 
We are excited to announce that LinkBio Inc. has entered into a joint research agreement with the laboratory of Professor Tomo Hoshino at the Faculty of Engineering, Kyushu University. (Feb 18, 2025)

• Our Aptamer Discovery Service Featured in Funakoshi News. 
Our “Aptamer Discovery Service using the MACE®-SELEX Method” was featured in the Dec 1, 2024 issue (No. 802) of Funakoshi News (Drug Discovery Support, p.25). (December 2, 2024)

• Article by Our CEO and CTO Published in Journal of Experimental Medicine (JEM)　Special Issue. (Sep 11, 2024)

• Patent Granted in South Korea for Aptamer Screening Method.
We are pleased to announce that the patent titled “Method for Screening Nucleic Acid Aptamers” (Applicants: The University of Tokyo and LinkBio Inc.) has been granted in South Korea. Patent Number: 10-2672039 (July 9, 2024)

• We’ve Won! LinkBio Selected for Major AMED Research Project.
We’re excited to share that LinkBio has been chosen to participate in a prestigious research initiative funded by the Japan Agency for Medical Research and Development (AMED)!Led by the University of Tokyo, with Nara Medical University and LinkBio as key collaborators, this project marks a major step forward in our commitment to cutting-edge medical innovation. (June 17, 2024)